222 related articles for article (PubMed ID: 7981204)
1. Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors.
Tsuda Y; Cygler M; Gibbs BF; Pedyczak A; Féthière J; Yue SY; Konishi Y
Biochemistry; 1994 Dec; 33(48):14443-51. PubMed ID: 7981204
[TBL] [Abstract][Full Text] [Related]
2. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin.
Féthière J; Tsuda Y; Coulombe R; Konishi Y; Cygler M
Protein Sci; 1996 Jun; 5(6):1174-83. PubMed ID: 8762149
[TBL] [Abstract][Full Text] [Related]
4. Interactions of hirudin-based inhibitor with thrombin: critical role of the IleH59 side chain of the inhibitor.
Tsuda Y; Szewczuk Z; Wang J; Yue SY; Purisima E; Konishi Y
Biochemistry; 1995 Jul; 34(27):8708-14. PubMed ID: 7612610
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the complex of human alpha-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6.
Zdanov A; Wu S; DiMaio J; Konishi Y; Li Y; Wu X; Edwards BF; Martin PD; Cygler M
Proteins; 1993 Nov; 17(3):252-65. PubMed ID: 8272424
[TBL] [Abstract][Full Text] [Related]
6. Bifunctional peptide boronate inhibitors of thrombin: crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide.
Skordalakes E; Elgendy S; Goodwin CA; Green D; Scully MF; Kakkar VV; Freyssinet JM; Dodson G; Deadman JJ
Biochemistry; 1998 Oct; 37(41):14420-7. PubMed ID: 9772168
[TBL] [Abstract][Full Text] [Related]
7. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond.
DiMaio J; Ni F; Gibbs B; Konishi Y
FEBS Lett; 1991 Apr; 282(1):47-52. PubMed ID: 2026264
[TBL] [Abstract][Full Text] [Related]
8. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.
Maraganore JM; Bourdon P; Jablonski J; Ramachandran KL; Fenton JW
Biochemistry; 1990 Jul; 29(30):7095-101. PubMed ID: 2223763
[TBL] [Abstract][Full Text] [Related]
9. Design of a linker for trivalent thrombin inhibitors: interaction of the main chain of the linker with thrombin.
Szewczuk Z; Gibbs BF; Yue SY; Purisima E; Zdanov A; Cygler M; Konishi Y
Biochemistry; 1993 Apr; 32(13):3396-404. PubMed ID: 8461303
[TBL] [Abstract][Full Text] [Related]
10. Nonpolar interactions of thrombin S' subsites with its bivalent inhibitor: methyl scan of the inhibitor linker.
Slon-Usakiewicz JJ; Purisima E; Tsuda Y; Sulea T; Pedyczak A; Féthière J; Cygler M; Konishi Y
Biochemistry; 1997 Nov; 36(44):13494-502. PubMed ID: 9354617
[TBL] [Abstract][Full Text] [Related]
11. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.
De Simone G; Lombardi A; Galdiero S; Nastri F; Della Morte R; Staiano N; Pedone C; Bolognesi M; Pavone V
Protein Sci; 1998 Feb; 7(2):243-53. PubMed ID: 9521099
[TBL] [Abstract][Full Text] [Related]
12. Potent bivalent thrombin inhibitors: replacement of the scissile peptide bond at P(1)-P(1)' with arginyl ketomethylene isosteres.
Steinmetzer T; Zhu BY; Konishi Y
J Med Chem; 1999 Aug; 42(16):3109-15. PubMed ID: 10447955
[TBL] [Abstract][Full Text] [Related]
13. Rational design and selection of bivalent peptide ligands of thrombin incorporating P4-P1 tetrapeptide sequences: from good substrates to potent inhibitors.
Su Z; Vinogradova A; Koutychenko A; Tolkatchev D; Ni F
Protein Eng Des Sel; 2004 Aug; 17(8):647-57. PubMed ID: 15358856
[TBL] [Abstract][Full Text] [Related]
14. Hirulog peptides with scissile bond replacements resistant to thrombin cleavage.
Kline T; Hammond C; Bourdon P; Maraganore JM
Biochem Biophys Res Commun; 1991 Jun; 177(3):1049-55. PubMed ID: 2059196
[TBL] [Abstract][Full Text] [Related]
15. Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms.
Priestle JP; Rahuel J; Rink H; Tones M; Grütter MG
Protein Sci; 1993 Oct; 2(10):1630-42. PubMed ID: 8251938
[TBL] [Abstract][Full Text] [Related]
16. Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed alpha-thrombin inhibitors.
Lombardi A; Nastri F; Della Morte R; Rossi A; De Rosa A; Staiano N; Pedone C; Pavone V
J Med Chem; 1996 May; 39(10):2008-17. PubMed ID: 8642559
[TBL] [Abstract][Full Text] [Related]
17. Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors.
Qiu X; Padmanabhan KP; Carperos VE; Tulinsky A; Kline T; Maraganore JM; Fenton JW
Biochemistry; 1992 Dec; 31(47):11689-97. PubMed ID: 1445905
[TBL] [Abstract][Full Text] [Related]
18. Rational design of hirulog-type inhibitors of thrombin.
Egner U; Hoyer GA; Schleuning WD
J Comput Aided Mol Des; 1994 Oct; 8(5):479-90. PubMed ID: 7876896
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin.
Rehse PH; Steinmetzer T; Li Y; Konishi Y; Cygler M
Biochemistry; 1995 Sep; 34(36):11537-44. PubMed ID: 7547884
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of noncoded amino acids into the N-terminal domain 1-47 of hirudin yields a highly potent and selective thrombin inhibitor.
De Filippis V; Russo I; Vindigni A; Di Cera E; Salmaso S; Fontana A
Protein Sci; 1999 Oct; 8(10):2213-7. PubMed ID: 10548068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
